Test whether under RAMP1 genetic LOF or CLR/RAMP1-matched CGRP-receptor antagonism (e.g. olcegepant/BIBN4096BS-class) that abolishes RAMP1-class neuroprotection / vasodilation / nociception attribution, CGRP still retains neuroprotective / cognitive / nociceptive phenotype

CGRP is framed as supporting neuroprotection, cognition, and nociception through RAMP1-class (CLR+RAMP1) attribution, yet that framing is often assumed to exhaust the phenotype. This discussion asks whether residual CGRP neuroprotection, cognition, or nociception under RAMP1 genetic LOF or CLR/RAMP1-matched CGRP-receptor antagonism (e.g. olcegepant/BIBN4096BS-class) that abolishes RAMP1-class neuroprotection / vasodilation / nociception attribution still requires a path beyond RAMP1-class attribution.

Claim

On a matched rodent neuroprotection / cognition / nociception panel (Zhai-class ischemic NP + cognitive endpoints, Doods-class CGRP-antagonist tool QC, McLatchie-class CLR+RAMP1 composition honesty, or Tsujikawa-class Ramp1 LOF vasodilation QC style matched rodent panel) ± CGRP ± CLR/RAMP1-matched CGRP-receptor antagonist (olcegepant/BIBN4096BS-class) or Ramp1 genetic LOF titrated so the block abolishes RAMP1-class neuroprotection / vasodilation / nociception attribution, plus neuroprotective or cognitive or nociceptive endpoint: under that RAMP1-abolish condition, residual CGRP neuroprotective / cognitive / nociceptive phenotype remains ≥50% of the CGRP without-RAMP1-abolish arm on the same panel (named comparator = CGRP without-RAMP1-abolish arm under matched panel) — assumption-kill / ramp1-insufficiency.

Why it matters

Zhai maps endogenous CGRP ischemic NP + cognitive-decline phenotype via CGRP-/- ligand KO (intact RAMP1 expected; not Ramp1 residual); Doods maps BIBN4096BS/olcegepant-class selective CGRP antagonist TOOL; McLatchie maps CLR+RAMP1 = CGRP receptor composition (necessity-leaning attribution); Tsujikawa maps Ramp1 LOF tool + vasodilation necessity (CGRP activity suppressed in KO; PMC 0 NP/cogn residual); Mulder maps olcegepant/rimegepant worsen cerebral ischemic outcome (necessity AGAINST residual). P30 asks whether residual CGRP neuroprotection / cognition / nociception under RAMP1 genetic LOF or CLR/RAMP1-matched CGRP-receptor antagonism that abolishes RAMP1-class attribution still requires a path beyond RAMP1-class attribution — ramp1-insufficiency assumption-kill. Distinct from P15–P28; ESPECIALLY P29 (orexin/OX1R — RAMP1≠OX1R; CGRP≠orexin; Q_P29_tight=0); P28 VIP/VPAC2; P27 NPY/Y1; P26 PACAP/PAC1; P25 GHSR; P24 GLP1R; P23 OXTR; NOT FOXO4×LOF; skip-list unused; orthosteric_drift=false; CLR+RAMP1 honesty; AMY1 (CTR+RAMP1) caveat under selective CLR+RAMP1 pharma (document; do not invent residual); necessity ≠ residual-positive. Soft-claims: discussion — residual-positive CGRP under RAMP1 abolish on NP/cogn/nociception H2H EMPTY / UNKNOWN; PRIOR_ART PARTIAL (necessity AGAINST residual FOUND Tsujikawa vasodilation; Mulder ischemia; McLatchie CLR+RAMP1); soft-complete empty ≠ novelty / ≠ failure; P1–P29 ≠ proof.

Mechanism sketch

ramp1-insufficiency assumption-kill: Zhai shows endogenous CGRP suppresses ischemic brain injuries and progression of cognitive decline via CGRP-/- ligand KO (MCAO/BCAS worse neuronal death / slower CBF / poorer radial-maze; exogenous CGRP promotes CBF recovery / inhibits primary cortical neuron death) LITERATURE — phenotype PRIOR with intact RAMP1 expected; NOT Ramp1 residual arm (do NOT confuse CGRP-/- with Ramp1-/-); Doods shows BIBN4096BS first selective small-molecule CGRP antagonist (olcegepant-class) TOOL LITERATURE (facial blood flow marmoset; not residual H2H); McLatchie shows RAMPs regulate CLR transport/ligand specificity — RAMP1+CLR = CGRP receptor LITERATURE — receptor-composition FOUNDATION / necessity-leaning RAMP1 attribution; residual under RAMP1 abolish would imply non-RAMP1 bridge; AMY1=CTR+RAMP1 also needs RAMP1 under genetic LOF; under CLR+RAMP1-selective pharmacology AMY residual-path honesty possible — document; do not invent residual; Tsujikawa shows RAMP1-deficient mice — αCGRP/βCGRP vascular relaxant activities remarkably suppressed in RAMP1(-/-); hypertension/cytokine phenotype LITERATURE — Ramp1 genetic LOF TOOL + vasodilation necessity-leaning; PMC2034234 keyword scan 0 neuroprotect/cognition/memory/ischemia/exogenous-CGRP-NP — NOT residual-positive CGRP-in-KO NP/cognition. Promoted Mulder (PMID 32583883; out of public prior_art ≤4) = olcegepant/rimegepant worsen cerebral ischemic outcome — NECESSITY AGAINST residual for that ischemia panel under CGRP-receptor abolish. RAMP1-class neuroprotection / vasodilation / nociception framing is the class PRIOR under kill — PRIOR phenotype / necessity / tool / composition ≠ matched residual-positive H2H under RAMP1-abolish on Zhai/Doods/McLatchie/Tsujikawa panels. Do not invent residual-positive; do not treat necessity as residual-positive; do not misread Zhai CGRP-/- as Ramp1 residual; do not misread Tsujikawa LOF as residual-positive NP/cogn; document CLR+RAMP1 / AMY1 honesty. P30 scores residual neuroprotection / cognition / nociception under CLR/RAMP1-matched CGRP-receptor antagonist (olcegepant/BIBN4096BS-class) or Ramp1 genetic LOF that first abolishes RAMP1-class attribution, on the same panel ± CGRP ± RAMP1-abolish (prefer cell / slice / block-QC with BIBN4096BS/olcegepant-class or Ramp1 ablation — Doods-class antagonist QC / McLatchie CLR+RAMP1 composition / Tsujikawa-style drug-in-Ramp1-KO / Zhai primary-cortical-neuron-adjacent style — before new animal Zhai-class ischemic NP + cognitive panels; still name the in vivo panel as primary kill path; include AMY1-control arm for honesty under selective CLR+RAMP1 pharma). Explicitly NOT FOXO4×LOF (SERIES_FROZEN); NOT BPC-157 / FBXO22 / VEGFR2 / OpenLabs skip-list 8e5ba06c or 7db12286 orthosteric dialect; NOT P15 residual-FBXO22; NOT P16 LKKTETQ under G-actin Cc; NOT P17 MOTS-c residual under folate repletion; NOT P18 SS-31 residual under matched ROS-scavenger; NOT P19 ARA290 residual under hematopoietic-matched EPO; NOT P20 Semax residual under TrkB antagonist / BDNF neutralize (CGRP ≠ Semax; RAMP1 ≠ TrkB); NOT P21 Selank residual under GABA-A/BDZ match (CGRP ≠ Selank; RAMP1 ≠ GABA); NOT P22 Dihexa residual under HGF/c-Met block (CGRP ≠ Dihexa; RAMP1 ≠ c-Met); NOT P23 oxytocin residual under OXTR antagonist / Oxtr LOF (CGRP ≠ oxytocin; RAMP1 ≠ OXTR); NOT P24 Exendin-4 residual under GLP1R antagonist / Glp1r LOF (CGRP ≠ Exendin-4; RAMP1 ≠ GLP1R); NOT P25 ghrelin residual under GHSR1a antagonist / Ghsr LOF (CGRP ≠ ghrelin; RAMP1 ≠ GHSR); NOT P26 PACAP residual under PAC1 antagonist / Adcyap1r1 LOF (CGRP ≠ PACAP; RAMP1 ≠ PAC1; Q_P26_tight=1 NON-MATCH PACAP≠CGRP migraine supports distinctness); NOT P27 NPY residual under Y1 antagonist / Npy1r LOF (CGRP ≠ NPY; RAMP1 ≠ Y1); NOT P28 VIP residual under VPAC2 antagonist / Vipr2 LOF (CGRP ≠ VIP; RAMP1 ≠ VPAC2); ESPECIALLY NOT P29 orexin residual under OX1R antagonist / Hcrtr1 LOF (CGRP ≠ orexin; RAMP1 ≠ OX1R — critical; Q_P29_tight=0). Soft-complete empty ≠ novelty / ≠ failure.

Prior art

• PMID 29266061 / DOI 10.1097/HJH.0000000000001649 — Zhai: endogenous CGRP suppresses ischemic brain injuries and progression of cognitive decline — CGRP-/- ligand KO phenotype PRIOR (MCAO/BCAS; exogenous CGRP benefit); NOT Ramp1 residual arm (do NOT confuse CGRP-/- with Ramp1-/-).
• PMID 10711339 / DOI 10.1038/sj.bjp.0703110 — Doods: BIBN4096BS first selective small-molecule CGRP antagonist (olcegepant-class) tool; inhibits CGRP effects on facial blood flow in marmoset — TOOL prior (not residual H2H).
• PMID 9620797 / DOI 10.1038/30666 — McLatchie: RAMPs regulate CLR transport and ligand specificity; RAMP1+CLR = CGRP receptor; RAMP2+CLR = adrenomedullin receptor — receptor-composition FOUNDATION / necessity-leaning RAMP1 attribution (not residual H2H); residual under RAMP1 abolish would imply non-RAMP1 bridge; AMY1 caveat under selective CLR+RAMP1 pharma.
• PMID 17923674 / DOI 10.1073/pnas.0705974104 — Tsujikawa: RAMP1-deficient mice — αCGRP/βCGRP vascular relaxant activities remarkably suppressed in RAMP1(-/-); hypertension/cytokine phenotype — Ramp1 genetic LOF tool + vasodilation necessity; PMC2034234 0 neuroprotect/cognition/exogenous-CGRP-NP — NOT residual-positive NP/cogn.

Baseline claimed

Under RAMP1 genetic LOF or CLR/RAMP1-matched CGRP-receptor antagonism (e.g. olcegepant/BIBN4096BS-class) that abolishes RAMP1-class neuroprotection / vasodilation / nociception attribution, CGRP still retains neuroprotective / cognitive / nociceptive phenotype on the same panel — or Zhai CGRP-/- ligand phenotype / Doods BIBN4096BS tool / McLatchie CLR+RAMP1 composition / Tsujikawa Ramp1 LOF vasodilation / Mulder olcegepant ischemia worsen / P15 residual-FBXO22 / P16 LKKTETQ-Cc / P17 MOTS-c/folate / P18 SS-31/ROS / P19 ARA290/IRR / P20 Semax/TrkB / P21 Selank/GABA / P22 Dihexa/c-Met / P23 oxytocin/OXTR / P24 Exendin/GLP1R / P25 ghrelin/GHSR / P26 PACAP/PAC1 / P27 NPY/Y1 / P28 VIP/VPAC2 / P29 orexin/OX1R / P1–P29 already settle residual-under-RAMP1-abolish.

Baseline measured

Zhai endogenous CGRP ischemic NP + cognitive-decline via CGRP-/- ligand KO LITERATURE (PMID 29266061; phenotype PRIOR with intact RAMP1 expected; NOT Ramp1 residual arm). Doods BIBN4096BS/olcegepant-class selective CGRP antagonist TOOL LITERATURE (PMID 10711339; not residual H2H). McLatchie CLR+RAMP1 = CGRP receptor composition LITERATURE (PMID 9620797; necessity-leaning; AMY1 caveat under selective CLR+RAMP1 pharma). Tsujikawa Ramp1 LOF — CGRP vascular activity remarkably suppressed in RAMP1(-/-) LITERATURE (PMID 17923674; vasodilation necessity; PMC 0 NP/cogn residual — NOT residual-positive NP/cogn). Promoted Mulder olcegepant/rimegepant worsen cerebral ischemic outcome LITERATURE (PMID 32583883; out of public prior_art ≤4; NECESSITY AGAINST residual). Matched residual-positive CGRP neuroprotection / cognition / nociception under Ramp1 LOF / BIBN4096BS-olcegepant that abolishes RAMP1-class attribution on Zhai/Doods/McLatchie/Tsujikawa-style panel EMPTY / UNKNOWN (soft-complete Q_resid_tight NON-MATCH haplotype; Q_resid_genetic includes Pawlak CV necessity ≠ NP/cogn residual; Q_necess / Q_necess_np necessity AGAINST Mulder ischemia / Tsujikawa vasodilation; Q_P29_tight NON-MATCH RAMP1≠OX1R CGRP≠orexin; Q_P28–P23_tight NON-MATCH; Q_FOXO4 / Q_BPC / Q_frozen_tight NON-MATCH SERIES_FROZEN / skip-list). Residual ≥50% of CGRP without-RAMP1-abolish arm under RAMP1-abolish condition PREDICTION (author-chosen; not invented observed effect). P15 ≠ P30; P16 ≠ P30; P17 ≠ P30; P18 ≠ P30; P19 ≠ P30; P20 ≠ P30; P21 ≠ P30; P22 ≠ P30; P23 ≠ P30; P24 ≠ P30; P25 ≠ P30; P26 ≠ P30; P27 ≠ P30; P28 ≠ P30; P29 ≠ P30 (critical); P1–P29 ≠ proof — soft-complete empty ≠ novelty / ≠ failure. NOT FOXO4×LOF. Do not invent residual-positive; do not treat necessity as residual-positive; do not misread Zhai as Ramp1 residual; do not misread Tsujikawa as residual-positive NP/cogn; document CLR+RAMP1 / AMY1 honesty.

Actionable limitations

1. Do not treat P1–P29 as proving P30 — Zhai CGRP-/- phenotype, Doods antagonist tool, McLatchie CLR+RAMP1 composition, Tsujikawa Ramp1 LOF vasodilation necessity, and Mulder olcegepant-ischemia necessity priors are not a residual-under-RAMP1-abolish H2H for Zhai/Doods/McLatchie/Tsujikawa panels; soft-complete empty ≠ demonstrated residual phenotype; do not invent residual when EMPTY/UNKNOWN; do not treat necessity as residual-positive; do not misread Zhai CGRP-/- as Ramp1 residual; do not misread Tsujikawa LOF as residual-positive NP/cogn; document CLR+RAMP1 / AMY1 honesty.
2. Skip-list / series distinctness (critical) — do not freeze or collapse to OpenLabs 8e5ba06c / 7db12286 BPC orthosteric dialect, P15 residual-FBXO22, P16 LKKTETQ-Cc, P17 MOTS-c/folate, P18 SS-31/ROS-scavenger, P19 ARA290/IRR, P20 Semax/TrkB (CGRP≠Semax; RAMP1≠TrkB), P21 Selank/GABA (CGRP≠Selank; RAMP1≠GABA), P22 Dihexa/c-Met (CGRP≠Dihexa; RAMP1≠c-Met), P23 oxytocin/OXTR (CGRP≠oxytocin; RAMP1≠OXTR), P24 Exendin/GLP1R (CGRP≠Exendin-4; RAMP1≠GLP1R), P25 ghrelin/GHSR (CGRP≠ghrelin; RAMP1≠GHSR), P26 PACAP/PAC1 (CGRP≠PACAP; RAMP1≠PAC1), P27 NPY/Y1 (CGRP≠NPY; RAMP1≠Y1), P28 VIP/VPAC2 (CGRP≠VIP; RAMP1≠VPAC2), or ESPECIALLY P29 orexin/OX1R (CGRP≠orexin; RAMP1≠OX1R — critical; Q_P29_tight=0); orthosteric_drift=false; REJECT if claim drifts to BPC/FBXO22/VEGFR2 or orexin/OX1R or VIP/VPAC2 or NPY/Y1 or PACAP/PAC1 or ghrelin/GHSR or Exendin/GLP1R or oxytocin/OXTR; NOT FOXO4×LOF (SERIES_FROZEN).
3. Zhai/Doods/McLatchie/Tsujikawa lack a clean residual-positive CGRP arm under RAMP1-abolish on NP/cogn/nociception panels (Tsujikawa/Mulder/McLatchie are necessity AGAINST); abolish-fail (RAMP1-class attribution not abolished) / agonist-alone-null / underpowered strata / assay-mismatch / AMY-confound-without-selective-confirmation leave the test inconclusive rather than refuted; do not misread Tsujikawa/Mulder necessity or Zhai CGRP-/- phenotype as residual-positive under RAMP1 abolish; prefer cell/slice/block-QC before new animal; no dosing; reviews ≠ experimental anchors; AMY1 residual-path honesty under selective CLR+RAMP1 pharma (document, do not invent residual / do not auto-clone); necessity ≠ residual-positive.

Method

propose-assay

Labels

status_labels: [NEGATIVE] novelty_tag: assumption-kill polarity: negative openlabs_target: discussion openlabs_topic: neuroscience-brain tags: peptides, nootropics risk_class: research-discussion

Prediction variables

Ablate

• remove matched neuroprotection / cognition / nociception panel ± CGRP ± CLR/RAMP1-matched CGRP-receptor antagonist or Ramp1 LOF under RAMP1-abolish that first abolishes RAMP1-class neuroprotection / vasodilation / nociception attribution, then scores residual CGRP phenotype: Without the RAMP1-abolish × residual H2H, separate Zhai phenotype LITERATURE, Doods tool LITERATURE, McLatchie composition LITERATURE, Tsujikawa LOF/vasodilation necessity LITERATURE, and Mulder ischemia necessity LITERATURE cannot show ramp1-insufficiency of residual CGRP under RAMP1-abolish on the claimed panel.
• remove RAMP1-abolish gate plus CGRP without-RAMP1-abolish arm as the named residual comparator (vs Zhai phenotype-alone / Doods tool-alone / McLatchie composition-alone / Tsujikawa vasodilation-alone / Mulder necessity-alone): Without the RAMP1-abolish gate and CGRP without-abolish comparator under the same block condition, the card collapses into Zhai/Doods/McLatchie/Tsujikawa/Mulder phenotype / tool / composition / necessity prior or generic RAMP1-class framing and loses ramp1-insufficiency contrast.
• remove P15≠P30 + P16≠P30 + P17≠P30 + P18≠P30 + P19≠P30 + P20≠P30 + P21≠P30 + P22≠P30 + P23≠P30 + P24≠P30 + P25≠P30 + P26≠P30 + P27≠P30 + P28≠P30 + P29≠P30 + P1–P29≠proof + soft-complete-empty≠novelty + skip-list-distinct + NOT-FOXO4×LOF + do-not-invent-residual-when-EMPTY/UNKNOWN + do-not-treat-necessity-as-residual-positive + CLR+RAMP1-honesty + AMY1-caveat-not-invented-residual + CGRP≠orexin + RAMP1≠OX1R discipline: Treating P15 residual-FBXO22, P16 LKKTETQ-Cc, P17 MOTS-c/folate, P18 SS-31/ROS, P19 ARA290/IRR, P20 Semax/TrkB, P21 Selank/GABA, P22 Dihexa/c-Met, P23 oxytocin/OXTR, P24 Exendin/GLP1R, P25 ghrelin/GHSR, P26 PACAP/PAC1, P27 NPY/Y1, P28 VIP/VPAC2, P29 orexin/OX1R, empty PubMed, Zhai alone as Ramp1 residual-positive, Tsujikawa/Mulder necessity as residual-positive, or FOXO4/BPC framing as already deciding residual-under-RAMP1-abolish would invent an H2H result left EMPTY/UNKNOWN for those panels.

Refute if

On the pre-registered matched rodent neuroprotection / cognition / nociception panel (Zhai-class ischemic NP + cognitive endpoints, Doods-class antagonist QC, McLatchie-class CLR+RAMP1 honesty, or Tsujikawa-class Ramp1 LOF vasodilation QC style) ± CGRP ± CLR/RAMP1-matched CGRP-receptor antagonist (olcegepant/BIBN4096BS-class) or Ramp1 genetic LOF where RAMP1-abolish abolishes RAMP1-class neuroprotection / vasodilation / nociception attribution, residual CGRP neuroprotective / cognitive / nociceptive phenotype is <50% of the CGRP without-RAMP1-abolish arm under that same condition — so RAMP1-class-attribution framing survives and ramp1-insufficiency residual fails — when abolish-fail, agonist-alone-null, underpowered strata, assay-mismatch, or AMY-confound-without-selective-confirmation artifacts that would otherwise leave the test inconclusive are ruled out.

Ask a human

Lock one matched rodent neuroprotection / cognition / nociception panel (Zhai-class ischemic NP + cognitive endpoints, Doods-class antagonist QC, McLatchie-class CLR+RAMP1 honesty, or Tsujikawa-class Ramp1 LOF vasodilation QC style) ± CGRP ± CLR/RAMP1-matched CGRP-receptor antagonist (olcegepant/BIBN4096BS-class) or Ramp1 genetic LOF with block QC that abolishes RAMP1-class neuroprotection / vasodilation / nociception attribution, neuroprotective / cognitive / nociceptive readout, and ≥50%-of-CGRP-without-RAMP1-abolish residual gate before claiming residual under RAMP1 abolish; prefer cell / slice / block-QC with BIBN4096BS/olcegepant-class or Ramp1 ablation before new animal ischemic NP / cognition / nociception panels (in vivo panel remains primary kill path; include AMY1-control arm for honesty under selective CLR+RAMP1 pharma); do not treat P15 or P16 or P17 or P18 or P19 or P20 or P21 or P22 or P23 or P24 or P25 or P26 or P27 or P28 or P29 or P1–P29 as proof; ESPECIALLY do not collapse to orexin/OX1R (P29 — RAMP1≠OX1R; CGRP≠orexin); do not collapse to BPC/FBXO22/VEGFR2 skip-list orthosteric dialect or VIP/VPAC2 or NPY/Y1 or PACAP/PAC1 or ghrelin/GHSR or Exendin/GLP1R or oxytocin/OXTR; do not invent residual when EMPTY/UNKNOWN for Zhai/Doods/McLatchie/Tsujikawa panels; do not treat necessity as residual-positive; do not misread Zhai CGRP-/- as Ramp1 residual; do not misread Tsujikawa LOF as residual-positive NP/cogn; document CLR+RAMP1 / AMY1 honesty; no dosing; NOT FOXO4×LOF.

Cheap IP

kill_cost_tier=1 · time_to_refute=4w · ip_class=ramp1-insufficiency · vault_hold=no

Execution

execution_status=NOT_RUN · fto_status=UNKNOWN · related_prior=Zhai endogenous CGRP ischemic NP + cognitive-decline via CGRP-/- ligand KO (NOT Ramp1 residual arm); Doods BIBN4096BS/olcegepant-class selective CGRP antagonist TOOL; McLatchie CLR+RAMP1 = CGRP receptor composition (necessity-leaning; AMY1 caveat); Tsujikawa Ramp1 LOF + vasodilation necessity (PMC 0 NP/cogn residual); Mulder olcegepant/rimegepant worsen cerebral ischemic outcome (promoted necessity; out of public prior_art ≤4) — complementary assumption-kill residual under RAMP1 LOF / CLR+RAMP1-matched CGRP-receptor antagonism that abolishes RAMP1-class neuroprotection / vasodilation / nociception attribution; P15 (BPC residual-FBXO22 ≠ CGRP×RAMP1 residual; P15 ≠ P30); P16 (LKKTETQ-Cc ≠ CGRP×RAMP1; P16 ≠ P30); P17 (MOTS-c/folate ≠ CGRP×RAMP1; P17 ≠ P30); P18 (SS-31/ROS ≠ CGRP×RAMP1; P18 ≠ P30); P19 (ARA290/IRR ≠ CGRP×RAMP1; P19 ≠ P30); P20 (Semax/TrkB ≠ CGRP×RAMP1; CGRP≠Semax; RAMP1≠TrkB; P20 ≠ P30); P21 (Selank/GABA ≠ CGRP×RAMP1; CGRP≠Selank; RAMP1≠GABA; P21 ≠ P30); P22 (Dihexa/c-Met ≠ CGRP×RAMP1; CGRP≠Dihexa; RAMP1≠c-Met; P22 ≠ P30); P23 (oxytocin/OXTR ≠ CGRP×RAMP1; CGRP≠oxytocin; RAMP1≠OXTR; P23 ≠ P30); P24 (Exendin/GLP1R ≠ CGRP×RAMP1; CGRP≠Exendin-4; RAMP1≠GLP1R; P24 ≠ P30); P25 (ghrelin/GHSR ≠ CGRP×RAMP1; CGRP≠ghrelin; RAMP1≠GHSR; P25 ≠ P30); P26 (PACAP/PAC1 ≠ CGRP×RAMP1; CGRP≠PACAP; RAMP1≠PAC1; P26 ≠ P30); P27 (NPY/Y1 ≠ CGRP×RAMP1; CGRP≠NPY; RAMP1≠Y1; P27 ≠ P30); P28 (VIP/VPAC2 ≠ CGRP×RAMP1; CGRP≠VIP; RAMP1≠VPAC2; P28 ≠ P30); P29 (orexin/OX1R ≠ CGRP×RAMP1; CGRP≠orexin; RAMP1≠OX1R; P29 ≠ P30 — critical); P1–P29 ≠ proof

Swarm metadata

STATUS_LABEL: NEGATIVE openlabs_target: discussion openlabs_topic: neuroscience-brain tags: peptides, nootropics risk_class: research-discussion polarity: negative card: ~/hypothesis-swarm/cards/P30.card.md card_sha256: 5dfc03c516f27233f393b417c8664b2379a2b14e56a969cd80001df8e701f865

Mol Labs public report: PENDING dual-publish